Literature DB >> 11815491

Disturbances in beta-cell function in impaired fasting glycemia.

Timon W van Haeften1, Walkyria Pimenta, Asimina Mitrakou, Mary Korytkowski, Trond Jenssen, Hannele Yki-Jarvinen, John E Gerich.   

Abstract

In a cross-sectional study, we assessed beta-cell function and insulin sensitivity index (ISI) with hyperglycemic clamps (10 mmol/l) in 24 subjects with impaired fasting glycemia (IFG, fasting plasma glucose [FPG] between 6.1 and 7.0 mmol/l), 15 type 2 diabetic subjects (FPG >7.0 mmol/l), and 280 subjects with normal fasting glycemia (NFG, FPG <6.1 mmol/l). First-phase insulin release (0-10 min) was lower in IFG (geometric mean 541 pmol/l.10 min; 95% confidence interval [CI] 416-702 pmol/l.10 min) and in type 2 diabetes (geometric mean 376 pmol/l.10 min; 95% CI 247-572 pmol/l.10 min) than NFG (geometric mean 814 pmol/l.10 min; 95% CI 759-873 pmol/l.10 min) (P < 0.001). Second-phase insulin secretion (140-180 min) was also lower in IFG (geometric mean 251 pmol/l; 95% CI 198-318 pmol/l; P = 0.026) and type 2 diabetes (geometric mean 157 pmol/l; 95% CI 105-235 pmol/l; P < 0.001) than NFG (geometric mean 295 pmol/l; 95% CI 276-315 pmol/l). IFG and type 2 diabetic subjects had a lower ISI (0.15 plus minus 0.02 and 0.16 plus minus 0.02 micromol/kg fat-free mass [FFM]/min/pmol/l, respectively) than NFG (0.24 plus minus 0.01 micromol/kg FFM/min/pmol/l, P < 0.05). We found a stepwise decline in first-phase (and second-phase) secretion in NFG subjects with progressive decline in oral glucose tolerance (P < 0.05). IFG subjects with impaired glucose tolerance (IGT) had lower first-phase secretion than NFG subjects with IGT (P < 0.02), with comparable second-phase secretion and ISI. NFG and IFG subjects with a diabetic glucose tolerance (2-h glucose >11.1 mmol/l) had a lower ISI than their respective IGT counterparts (P < 0.05). We conclude that the early stages of glucose intolerance are associated with disturbances in beta-cell function, while insulin resistance is seen more markedly in later stages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815491     DOI: 10.2337/diabetes.51.2007.s265

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

1.  Albuminuria in prediabetes: time to intervene?

Authors:  Venkata Ranga Rao Kodali
Journal:  Endocrine       Date:  2014-11-05       Impact factor: 3.633

Review 2.  Diabetes and cardiovascular autonomic dysfunction: application of animal models.

Authors:  Katia De Angelis; Maria Claudia Irigoyen; Mariana Morris
Journal:  Auton Neurosci       Date:  2008-12-02       Impact factor: 3.145

3.  From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation.

Authors:  Fida Bacha; Sojung Lee; Neslihan Gungor; Silva A Arslanian
Journal:  Diabetes Care       Date:  2010-06-30       Impact factor: 19.112

Review 4.  Pathophysiology of prediabetes.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

5.  Pharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood.

Authors:  Dayu Lv; Sandip D Kulkarni; Alice Chan; Stephen Keith; Ron Pettis; Boris P Kovatchev; Leon S Farhi; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-03-09

6.  Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance.

Authors:  E Ferrannini; A Gastaldelli; Y Miyazaki; M Matsuda; M Pettiti; A Natali; A Mari; R A DeFronzo
Journal:  Diabetologia       Date:  2003-07-23       Impact factor: 10.122

7.  The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance.

Authors:  Muhammad A Abdul-Ghani; Masafumi Matsuda; Rucha Jani; Christopher P Jenkinson; Dawn K Coletta; Kohei Kaku; Ralph A DeFronzo
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

8.  Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.

Authors:  M Laakso; J Zilinskaite; T Hansen; T Welløv Boesgaard; M Vänttinen; A Stancáková; P-A Jansson; F Pellmé; J J Holst; T Kuulasmaa; M L Hribal; G Sesti; N Stefan; A Fritsche; H Häring; O Pedersen; U Smith
Journal:  Diabetologia       Date:  2007-12-14       Impact factor: 10.122

9.  Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function.

Authors:  Annemarie M Simonis-Bik; Giel Nijpels; Timon W van Haeften; Jeanine J Houwing-Duistermaat; Dorret I Boomsma; Erwin Reiling; Els C van Hove; Michaela Diamant; Mark H H Kramer; Robert J Heine; J Antonie Maassen; P Eline Slagboom; Gonneke Willemsen; Jacqueline M Dekker; Elisabeth M Eekhoff; Eco J de Geus; Leen M 't Hart
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

10.  Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.

Authors:  Anthony J Hanley; Bernard Zinman; Patrick Sheridan; Salim Yusuf; Hertzel C Gerstein
Journal:  Diabetes Care       Date:  2009-12-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.